Case Form
Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
Biohaven issued a press release on March 3, 2025, reporting its financial results for the fourth quarter and full year 2024, as well as reporting recent business developments. Among other items, Biohaven reported a loss of $1.71 per share for the quarter, while analysts were expecting a loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company’s BHV-7000 drug in bipolar mania “did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure”.
Following this news, Biohaven’s stock price fell over 13% on the same day.